BSE filing, NSE: ADIRASA. Summary written from the filing by ALFA Finder's alert engine.
Genpharmasec Ltd: key numbers
- Share price
- ₹1.04
- Market cap
- ₹57.59 Cr
- Revenue (annual)
- ₹139.9 Cr
- Net profit (annual)
- ₹1.60 Cr
- P/E (TTM)
- -472.7×Sector 47.2×
- Promoter holding
- 32.06%+2.08% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Genpharmasec Ltd
All →Genpharmasec Financial Results
Genpharmasec approved unaudited half-year results and planned sale of its wholly owned subsidiary Clinigenome India. Company Secretary Hardik Makwana resigns effective 16 November 2026.
Genpharmasec Board Meeting Date
Genpharmasec Ltd will hold a Board meeting on 03 Nov 2026. Agenda includes proposing approval of Q2/H1 FY27 unaudited results.
Genpharmasec Other Announcement
Genpharmasec Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing provides a standard breakdown of promoter and public shareholding.
Genpharmasec Annual General Meeting
Genpharmasec Limited conducted its 34th Annual General Meeting on September 29, 2026. Shareholders considered resolutions including the adoption of FY26 financial statements and director re-appointments.
Genpharmasec Annual Report
Genpharmasec Ltd filed its 34th Annual Report for FY 2025-26 with BSE, including the AGM notice for 29 September 2026. The report covers audited financials, board updates, and governance disclosures.
Genpharmasec Management Change
Genpharmasec Limited has re-appointed Sohan Chaturvedi as Executive Director for a 36-month term effective April 26, 2027. This change is approved by the Board.
Other management change announcements
All →Bayer Cropscience Management Change
Bayer CropScience noted Dr. Thomas Hoffmann's resignation as director, effective November 30, 2026. It appointed Christiane Temminghoff as additional director from December 1, 2026.
Suyog Telematics Management Change
Suyog Telematics appointed Pankaj Mehta as Non-Executive Independent Director, effective December 1, 2026, for a 36-month term. Approved at the November 3, 2026 board meeting.
Timex Group India Management Change
Timex Group India's board approved B S R & Co. LLP as statutory auditor for five years, subject to shareholder approval. The appointment replaces Deloitte Haskins & Sells, whose second term ends in 2027.
- Execution
- 5 consecutive years, from conclusion of 39th AGM (2027) to conclusion of 44th AGM (2032)
J G Chemicals Management Change
J.G. Chemicals appointed Kaushik Roy and Sunil Duggal as Non-Executive Independent Directors for 36-month terms, effective 3 November 2026. Both bring extensive industrial and chemicals leadership experience.
GlaxoSmithKline Pharmaceuticals Management Change
GlaxoSmithKline Pharmaceuticals appointed Sandeep Seth as Head - Ethics & Compliance, effective 3 November 2026. He brings over 20 years of compliance and governance experience.
Autofurnish Management Change
Autofurnish Limited appointed Ms. Nisha Nagarkoti as Company Secretary and Compliance Officer effective 3 November 2026, at the board meeting held that day. No monetary amount is involved.